Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution

TY - JOUR

T1 - Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution

AU - Well, Lennart

AU - Rausch, Vanessa Hanna

AU - Adam, Gerhard

AU - Henes, Frank Oliver

AU - Bannas, Peter

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2017/7

Y1 - 2017/7

N2 - Purpose Varying frequencies (5 - 18 %) of contrast-related transient severe motion (TSM) imaging artifacts during gadoxetate disodium-enhanced arterial phase liver MRI have been reported. Since previous reports originated from the United States and Japan, we aimed to determine the frequency of TSM at a German institution and to correlate it with potential risk factors and previously published results. Materials and Methods Two age- and sex-matched groups were retrospectively selected (gadoxetate disodium n = 89; gadobenate dimeglumine n = 89) from dynamic contrast-enhanced MRI examinations in a single center. Respiratory motion-related artifacts in non-enhanced and dynamic phases were assessed independently by two readers blinded to contrast agents on a 4-point scale. Scores of ≥ 3 were considered as severe motion artifacts. Severe motion artifacts in arterial phases were considered as TSM if scores in all other phases were < 3. Potential risk factors for TSM were evaluated via logistic regression analysis. Results For gadoxetate disodium, the mean score for respiratory motion artifacts was significantly higher in the arterial phase (2.2 ± 0.9) compared to all other phases (1.6 ± 0.7) (p < 0.05). The frequency of TSM was significantly higher with gadoxetate disodium (n = 19; 21.1 %) than with gadobenate dimeglumine (n = 1; 1.1 %) (p < 0.001). The frequency of TSM at our institution is similar to some, but not all previously published findings. Logistic regression analysis did not show any significant correlation between TSM and risk factors (all p > 0.05). Conclusion We revealed a high frequency of TSM after injection of gadoxetate disodium at a German institution, substantiating the importance of a diagnosis-limiting phenomenon that so far has only been reported from the United States and Japan. In accordance with previous studies, we did not identify associated risk factors for TSM. Key Points:  · Gadoxetate disodium causes TSM in a relevant number of patients.. · The frequency of TSM is similar between the USA, Japan and Germany.. · To date, no validated risk factors for TSM could be identified.. Citation Format · Well L, Rausch VH, Adam G et al. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution. Fortschr Röntgenstr 2017; 189: 651 - 660.

AB - Purpose Varying frequencies (5 - 18 %) of contrast-related transient severe motion (TSM) imaging artifacts during gadoxetate disodium-enhanced arterial phase liver MRI have been reported. Since previous reports originated from the United States and Japan, we aimed to determine the frequency of TSM at a German institution and to correlate it with potential risk factors and previously published results. Materials and Methods Two age- and sex-matched groups were retrospectively selected (gadoxetate disodium n = 89; gadobenate dimeglumine n = 89) from dynamic contrast-enhanced MRI examinations in a single center. Respiratory motion-related artifacts in non-enhanced and dynamic phases were assessed independently by two readers blinded to contrast agents on a 4-point scale. Scores of ≥ 3 were considered as severe motion artifacts. Severe motion artifacts in arterial phases were considered as TSM if scores in all other phases were < 3. Potential risk factors for TSM were evaluated via logistic regression analysis. Results For gadoxetate disodium, the mean score for respiratory motion artifacts was significantly higher in the arterial phase (2.2 ± 0.9) compared to all other phases (1.6 ± 0.7) (p < 0.05). The frequency of TSM was significantly higher with gadoxetate disodium (n = 19; 21.1 %) than with gadobenate dimeglumine (n = 1; 1.1 %) (p < 0.001). The frequency of TSM at our institution is similar to some, but not all previously published findings. Logistic regression analysis did not show any significant correlation between TSM and risk factors (all p > 0.05). Conclusion We revealed a high frequency of TSM after injection of gadoxetate disodium at a German institution, substantiating the importance of a diagnosis-limiting phenomenon that so far has only been reported from the United States and Japan. In accordance with previous studies, we did not identify associated risk factors for TSM. Key Points:  · Gadoxetate disodium causes TSM in a relevant number of patients.. · The frequency of TSM is similar between the USA, Japan and Germany.. · To date, no validated risk factors for TSM could be identified.. Citation Format · Well L, Rausch VH, Adam G et al. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution. Fortschr Röntgenstr 2017; 189: 651 - 660.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Artifacts

KW - Ascites

KW - Carcinoma, Hepatocellular

KW - Contrast Media

KW - Female

KW - Gadolinium DTPA

KW - Germany

KW - Humans

KW - Infusions, Intravenous

KW - Liver

KW - Liver Cirrhosis

KW - Liver Neoplasms

KW - Lung Diseases

KW - Magnetic Resonance Imaging

KW - Male

KW - Meglumine

KW - Middle Aged

KW - Organometallic Compounds

KW - Pleural Effusion

KW - Risk Factors

KW - Young Adult

KW - Comparative Study

KW - Evaluation Studies

KW - Journal Article

U2 - 10.1055/s-0043-102940

DO - 10.1055/s-0043-102940

M3 - SCORING: Journal article

C2 - 28445909

VL - 189

SP - 651

EP - 660

JO - ROFO-FORTSCHR RONTG

JF - ROFO-FORTSCHR RONTG

SN - 1438-9029

IS - 7

ER -